OTCMLDXHF
Market cap22mUSD
Dec 23, Last price
0.03USD
Name
Lumos Diagnostics Holdings Ltd
Chart & Performance
P/E
—
P/S
2.02
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
93.94%
Rev. gr., 5y
19.96%
Revenues
11m
+5.66%
Net income
-9m
L-4.22%
CFO
946k
P
Profile
Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | |
| Income | |||||||
Revenues | 11,131 5.66% | 10,535 -9.42% | 11,630 -38.32% | ||||
Cost of revenue | 14,839 | 15,208 | 27,634 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (3,708) | (4,673) | (16,004) | ||||
NOPBT Margin | |||||||
Operating Taxes | 2,366 | 189 | |||||
Tax Rate | |||||||
NOPAT | (3,708) | (7,039) | (16,193) | ||||
Net income | (8,592) -4.22% | (8,971) -80.38% | (45,724) 204.22% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 4,999 | 7,870 | |||||
BB yield | |||||||
| Debt | |||||||
Debt current | 954 | 2,038 | 968 | ||||
Long-term debt | 15,166 | 16,186 | 13,420 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 1 | ||||||
Net debt | 9,641 | 15,209 | 6,410 | ||||
| Cash flow | |||||||
Cash from operating activities | 946 | (9,638) | (18,036) | ||||
CAPEX | (52) | (155) | (4,355) | ||||
Cash from investing activities | (98) | 4,307 | (4,355) | ||||
Cash from financing activities | 2,630 | 652 | (10,919) | ||||
FCF | (628) | (4,632) | (12,284) | ||||
| Balance | |||||||
Cash | 6,479 | 3,015 | 7,978 | ||||
Long term investments | |||||||
Excess cash | 5,922 | 2,488 | 7,396 | ||||
Stockholders' equity | 7,109 | 10,176 | 17,885 | ||||
Invested Capital | 9,247 | 16,795 | 17,682 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 463,194 | 234,843 | 152,324 | ||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | (561) | (1,641) | (13,587) | ||||
EV/EBITDA | |||||||
Interest | 975 | 371 | 172 | ||||
Interest/NOPBT | |||||||